Jun 08, 2020
Roxadustat Demonstrates Non-Inferiority to Darbepoetin in Phase 3 DOLOMITES Study of Anemia in Non-Dialysis-Dependent Adult Patients with Chronic Kidney Disease
May 05, 2020
Akebia Therapeutics Announces Positive Top-Line Results from Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients on Dialysis
Nov 27, 2019
The Erythropoietin Stimulating Agents Market in Latin America (2019-2027): Data on Epoetin-Alfa, Epoetin-Beta, Epoetin-Theta, Darbepoetin-Alfa, and Other ESAs
Jul 31, 2018
Pfizer's Retacrit, the First Erythropoietin Stimulating Agent to be FDA Approved, Not Likely to See Rapid Adoption in the US Dialysis Market
May 31, 2018
Biosimilars in Nephrology: Pfizer's Retacrit Gets FDA Clearance and Prepares to Challenge Amgen's Anemia Franchise Head On
May 15, 2018
FDA approves first epoetin alfa biosimilar for the treatment of anemia
May 08, 2018
The US Renal Anemia Market Sees Some Shifting As Mircera Use Expands Beyond Fresenius Medical Care Clinics and Auryxia Makes its Debut with a New Iron Deficiency Anemia Indication in the Pre-Dialysis Setting
Feb 07, 2018
Global Erythropoietin Drugs Market 2017-2025 by Drug & Application Type - A $19.65 Billion Market Opportunity
Dec 12, 2017
Global Chronic Kidney Disease (CKD) Drugs Market Forecast 2018-2028
Jun 22, 2017
Erythropoietin (EPO) Drugs Market to Reach $17.4 Billion by 2025 - Number of People Suffering From Anemia Expected to Increase - Research and Markets
Jun 22, 2017
Erythropoietin Drugs Market Size Worth $17.4 Billion by 2025: Grand View Research, Inc.